Loading stock data…
Revolution Medicines (RVMD)
$192.62+10.54 (+5.79%)
After Hours$192.74+0.12 (+0.06%)· Last close Jun 29
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revolution Medicines, Inc. in the Healthcare sector is trading at $192.62 with a market capitalization of $33.2B. Wall Street consensus targets $188.57 (21 analysts), implying a -2.1% move over the next 12 months. The stock is currently near its 52-week high of $192.80, remaining 94.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$445.22M↓ | -$361.63M↓ | -$315.27M↓ | -$264.71M↓ | -$240.76M |
| Net Income | -$453.82M↓ | -$364.89M↓ | -$305.21M↓ | -$247.79M↓ | -$213.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as m...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$33.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-91.45%
Volume
Today's trading volume
5.28M
Recent News
This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In.
XBI has “moved higher a record 12 of 13 months,” Mizuho healthcare sector specialist Jared Holz wrote Friday.
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in its business and a share price that looks like a mistake.
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best hot stocks to buy for June. On June 8, RBC Capital reiterated an Outperform rating on Revolution Medicines Inc. (NASDAQ:RVMD) and a $182 price target. The research firm remains bullish on the company’s outlook for candidate drug daraxonrasib (formerly referred to as daraxibart), which demonstrated an […]